AVI BioPharma, Inc. (AVII) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AVII Hot Sheet
Price: $0.66 --0%
Financial Fact:
Net income (loss) and comprehensive income (loss): -56.74M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Net income (loss) and comprehensive income (loss): -56.74M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
AVI BioPharma, Inc. (NASDAQ: AVII) reported Q1 EPS of ($0.13), $0.06 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $11.2 million versus the consensus estimate of $11.05 million.
For earnings history and earnings-related data on AVI BioPharma, Inc. (AVII) click here.
For earnings history and earnings-related data on AVI BioPharma, Inc. (AVII) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Marriott International (MAR) PT Lowered to $141 at Jefferies
- VivoPower posts $6.8M revenue and $0.6M profit in Q1 FY2027
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
